Sharklet Technologies Inc. has taken another step in commercializing bacteria-inhibiting, micro-texture surface technology.
The Aurora, Colo., firm has announced it has lined up additional capital from Altria Ventures that should accelerate its growth and development of the technology.
Sharklet is taking an unusual approach to bacteria control. Its technology relies on a distinct, repeating series of interlocking, raised micro-features on surfaces that reduce the survival, colonization and transfer of bacteria. Bacteria don’t like to grow on such surfaces, according to Sharklett. The firm’s pattern is manufactured onto adhesive-backed skins that can be applied to high-touch areas.
The company’s work includes medical devices that act as conduits for bacterial access to the body. Such devices include an endotracheal tube and a central venous catheter. Sharklet is also working on consumer applications of the technology.
Sharklet says widespread use of bacteria-killing antibiotics is causing bacteria to develop immunity to them and that its approach does not promote mutation and antibiotic resistance.
“As we grapple with the increasing challenges in the fight against bacteria such as MRSA, Pseudomonas aeroginosa and others, we are motivated to advance new technologies that arm us in the fight but don’t negatively impact humans or the environment,” states Sharklet CEO Mark Spiecker in a news release.
Altria Ventures is the venture capital subsidiary of Altria Group Inc. of Richmond, Va.
Sharklet tel. 720-859-4070.